KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Inventory (2017 - 2025)

Amneal Pharmaceuticals has reported Change in Inventory over the past 9 years, most recently at $20.2 million for Q4 2025.

  • Quarterly results put Change in Inventory at $20.2 million for Q4 2025, down 61.18% from a year ago — trailing twelve months through Dec 2025 was $87.0 million (down 33.33% YoY), and the annual figure for FY2025 was $87.0 million, down 33.33%.
  • Change in Inventory for Q4 2025 was $20.2 million at Amneal Pharmaceuticals, down from $30.8 million in the prior quarter.
  • Over the last five years, Change in Inventory for AMRX hit a ceiling of $52.0 million in Q4 2024 and a floor of -$16.6 million in Q4 2021.
  • Median Change in Inventory over the past 5 years was $23.2 million (2023), compared with a mean of $24.8 million.
  • Peak annual rise in Change in Inventory hit 630.13% in 2021, while the deepest fall reached 150.3% in 2021.
  • Amneal Pharmaceuticals' Change in Inventory stood at -$16.6 million in 2021, then skyrocketed by 166.57% to $11.1 million in 2022, then surged by 108.58% to $23.1 million in 2023, then surged by 125.14% to $52.0 million in 2024, then plummeted by 61.18% to $20.2 million in 2025.
  • The last three reported values for Change in Inventory were $20.2 million (Q4 2025), $30.8 million (Q3 2025), and $22.8 million (Q2 2025) per Business Quant data.